Serina Therapeutics Statistics
Total Valuation
SER has a market cap or net worth of $41.99 million. The enterprise value is $22.18 million.
| Market Cap | 41.99M |
| Enterprise Value | 22.18M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SER has 15.00 million shares outstanding. The number of shares has increased by 30.50% in one year.
| Current Share Class | 15.00M |
| Shares Outstanding | 15.00M |
| Shares Change (YoY) | +30.50% |
| Shares Change (QoQ) | +36.01% |
| Owned by Insiders (%) | 67.19% |
| Owned by Institutions (%) | 2.72% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.80 |
| P/TBV Ratio | 2.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.65, with a Debt / Equity ratio of 0.17.
| Current Ratio | 6.65 |
| Quick Ratio | 6.12 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -43.06 |
Financial Efficiency
Return on equity (ROE) is -207.94% and return on invested capital (ROIC) is -133.96%.
| Return on Equity (ROE) | -207.94% |
| Return on Assets (ROA) | -92.30% |
| Return on Invested Capital (ROIC) | -133.96% |
| Return on Capital Employed (ROCE) | -116.37% |
| Weighted Average Cost of Capital (WACC) | 4.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.34M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SER has paid $18,000 in taxes.
| Income Tax | 18,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.81% in the last 52 weeks. The beta is -0.00, so SER's price volatility has been lower than the market average.
| Beta (5Y) | -0.00 |
| 52-Week Price Change | -47.81% |
| 50-Day Moving Average | 2.09 |
| 200-Day Moving Average | 2.41 |
| Relative Strength Index (RSI) | 74.44 |
| Average Volume (20 Days) | 47,006 |
Short Selling Information
The latest short interest is 222,920, so 1.49% of the outstanding shares have been sold short.
| Short Interest | 222,920 |
| Short Previous Month | 285,430 |
| Short % of Shares Out | 1.49% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | -13.16M |
| Operating Income | -25.66M |
| Pretax Income | -21.17M |
| Net Income | -21.43M |
| EBITDA | -25.59M |
| EBIT | -25.66M |
| Earnings Per Share (EPS) | -$1.93 |
Balance Sheet
The company has $23.02 million in cash and $3.21 million in debt, with a net cash position of $19.82 million or $1.32 per share.
| Cash & Cash Equivalents | 23.02M |
| Total Debt | 3.21M |
| Net Cash | 19.82M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 18.73M |
| Book Value Per Share | 0.74 |
| Working Capital | 21.27M |
Cash Flow
In the last 12 months, operating cash flow was -$21.14 million and capital expenditures -$66,000, giving a free cash flow of -$21.20 million.
| Operating Cash Flow | -21.14M |
| Capital Expenditures | -66,000 |
| Depreciation & Amortization | 76,000 |
| Net Borrowing | 4.91M |
| Free Cash Flow | -21.20M |
| FCF Per Share | -$1.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SER does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.50% |
| Shareholder Yield | -30.50% |
| Earnings Yield | -51.03% |
| FCF Yield | -50.49% |
Analyst Forecast
The average price target for SER is $9.50, which is 239.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 239.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |